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I. Abstract 
Influenza has an extensive history of crippling global populations and remains 
prevalent due to a high mutation rate. This feature of influenza explains why new 
vaccines are developed and administered annually, yet no effective treatment for severe 
cases exist. Previous findings have shown an increase of certain microRNAs (miRs) in 
response to influenza infection. Examining the role of these molecules, specifically miR-
155, may reveal critical knowledge on disease development. This small nucleic acid’s 
expression increases consistently over a 6-day course of influenza infection in a murine 
model (C57BL/6). This leads us to believe that miR-155 plays an important role in the 
inflammatory response to influenza infection, leading to acute respiratory distress 
syndrome (ARDS), a condition of major clinical relevance. 
Alveolar type 2 (ATII) cells are a key cell type in the distal lung and are also a 
primary target for influenza A viruses. Infected and non-infected population of these 
cells can be isolated by utilizing a genetically engineered fluorescent virus and flow-
sorting based on fluorescence. Subsequent real-time PCR allows for quantification 
of miR-155 and its target genes. miR-155 levels are higher in mCherry-positive ATII 
cells compared to mCherry-negative cells from mice infected with fluorescent PR8-
mCherry influenza virus. Target genes of miR-155, including antiviral factors 
and regulators of cytokine production, have been shown to differ in expression between 
virally infected and uninfected populations ATII cells of the same mouse. 
The information drawn from this project may lead to identification of new targets 
for therapeutic agents which enhance the host's immune capability to fight off newly 
emerging strains of influenza. 
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II. Introduction: 
A. Historical Background   
 Influenza is a human pathogen with a deep-rooted history in public health. While 
influenza was first described in the 16th century, the most notable outbreak of the viral 
disease occurred in 1918. Contrary to its name “Spanish influenza”, the outbreak did not 
localize itself to Spain but reached pandemic proportions of transmission and spread. 
The 1918 pandemic remains one of the most fatal biological events in entire human 
history, comparable to the bubonic plague. It is estimated that more than 50 million 
people died globally1. Although unknown at the time, the influenza virus cross over from 
avian reservoirs and is therefore considered a major zoonotic disease today2. 
B. Influenza A Virus  
The type A and B subsets of influenza is responsible for annual strains of 
influenza which affect human and animal populations. Influenza A virus (IAV) is a 
negative sense, segmented, single stranded RNA virus belonging to the 
orthomyxoviridae family. The segmented nature of influenza virus allows for genes 
segments to be exchanged between another different virions within the same host cell3. 
Subsequent shifts in the hemagglutinin and neuraminidase glycoproteins of the viral 
surface result in novel antigens, meaning that the host immune cells will not recognize 
the virus upon exposure. The consequence of this process of antigenic shift is that 
preventative measures against the virus, such as vaccination, are insufficient in 
producing long term immunity due to the seasonal variability in viral strains. Antigenic 
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drift, or the gradual changes in genetic sequence of the virus, also contribute to 
difficulties in managing public health responses to influenza strains.  
C. Alveolar Type II Cells 
Alveolar type II (ATII) cells are one of two epithelial cell types that line the 
alveolar surface. Although ATII cells only make up roughly 5% of the surface, they 
account for about 50% of total cells. ATII cells have major roles pulmonary function. Key 
functions of this cell type include vectorial ion transport, differentiation in ATI cells during 
lung repair after injury, regulation of monocyte transfer across epithelium, and the 
secretion of lung surfactant lipid and proteins4,5.  
  Not only do ATII cells perform critical functions for maintaining lung homeostasis, 
but they are also a primary site of IAV replication in individuals with severe lower  
respiratory tract disease6 and contribute to the innate immune response to this pathogen. 
D. MicroRNA 
 MicroRNAs span from 21-25 nucleotides in length and contribute to a dynamic 
range of regulatory functions in biological systems7, by exerting effects on 
transcriptomics by binding specific mRNA consensus sequences to degrade the nucleic 
acid or repress translation8. 
Specifically of interest in regards to influenza infection is the expression of 
microRNA-155 (miR-155) and the regulatory role it plays in the ATII cellular response of 
influenza infection. miR-155 has been shown to play an important role in the pro-
inflammatory response of respiratory epithelial cells to a variety of insults10. In preliminary 
studies conducted by the Davis lab, it was reported that miR-155 expression is 
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progressively up-regulated over the course of 6 days in ATII cells from mice infected with 
influenza A/WSN/33 (H1N1) IAV. However, not all these ATII cells contain replicating 
virus. This observation led to the hypothesis that miR-155 expression profiles will differ 
between ATII cells containing replicating virus, and those which do not contain non-
replicating virus. miR-155 expression is likely not homogeneous within a population of 
isolated ATII cells, making it important to develop a model for distinguishing infected 
versus non-infected cells.  
Figure 4: RT-PCR probes measured 
changes in microRNA expression in ATII 
cells at 2 and 6 days post infection with 
WSN influenza A virus 
 
E. Project Overview 
 Since microRNAs have been shown to exert a broad regulatory effect on the 
expression of genes in an in vivo model, it follows that there may be observable 
changes in regulation in response to influenza infection. We aimed not only to 
characterize how IAV alters the dynamics of a whole-lung in a WT and miR-155 
knockout model, but also how miR-155 expression differs from ATII cells containing 
replicating virus and ATII cells not containing replicating virus. Consequently, we aimed 
to assess how miR-155 targets genes are expressed in these different cellular 
phenotypes. The knowledge of the impact of miR-155 at the cellular level may help lead 
to identification of potential targets for host-directed therapeutics against influenza 
infection. 
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III. Materials and Methods 
A. Mouse Model and Infection 
Wild-type (WT) C57BL/6 mice were obtained from Charles River Laboratories 
between eight and twelve weeks of age. After sedation using a mixture of ketamine and 
xylazine, mice were inoculated with 50,000 plaque-forming units (PFU) of 
PR8/mCherry/NS1 (H1N1) virus9. Control mice were mock-infected with the inoculum 
virus diluent (0.1% BSA in PBS). The 50 µL inoculum was administered intranasally 
over the course of 5-10 minutes. Genetically engineered through a ATII cell-specific cre-
lox system, a strain of C57BL/6 miR-155 knockout (miR-155 KO) mice were also used 
in this study. 
B. Mouse Monitoring 
Mock-infected and infected mice were closely monitored for the duration of the 
experiment, either 2, 4, or 6 days. Pulse Oximeter and body weight measurements were 
performed every other day throughout the experiments.  
C. ATII Cell Isolation 
     Alveolar type II cells were isolated at either 2, 4, or 6 days post-infection (dpi). The 
lungs were perfused with heparin solution, before being placed in suspension for 
dispase and DNAase digestion10. Filtrations were performed using 100 and 25um nylon 
meshes to obtain a single cell suspension. Cell counts were performed and viability 
assessed via trypan blue staining. Based on these cell counts, appropriate quantities of 
biotinylated antibodies against CD45, CD16/32, CD31, CD104, and TER119 were 
added to each sample. Following a 20-minute incubation, streptavidin beads were 
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added to bind the antibodies and cells were incubated for an additional 20 minutes on 
ice. The cell suspensions were sorted through automacs magnetic columns, to isolate 
populations of alveolar type II cells by negative selection. Purity of isolated ATII cells 
were confirmed by flow cytometry. 
D. Aria III Flow Sorting 
 Isolated alveolar type II cells were sorted by flow cytometry based on mCherry 
fluorescence using a 561 nm laser of an Aria III instrument (OSUCCC Analytical 
Cytometry Core). Based on gating against a mock-infected pool of isolated cells, cells 
expressing mCherry fluorescence were isolated in addition to cells not expressing 
fluorescence within the same murine lung. Total cell counts and percentage of each 
population were obtained, respective to total ATII cells isolated. 
E. PCR Array Analysis of Genes Associated with miR-155 
 Total RNA of ATII cells was isolated using TRIzol reagent( Invitrogen: Carlsbad, 
California) and purified using a miRNeasy kit (Qiagen: Hilden, Germany). Quantification 
of the RNA was performed using a Nanodrop ND-1000 spectrophotometer 
(ThermoScientific: Carlsbad, California). For PCR array analysis >100ng of total RNA 
was reverse transcribed to cDNA using the RT2 First Strand kit as per manufacturer’s 
instructions (Sabbiosciences: Frederick, Maryland). The cDNA was preamplified using a 
miR-155 pathway primer mix (Qiagen: Hilden, Germany) and added to miR-155 target 
array plates(PAMM-6002ZC-12) in 25 µL volumes. To normalize data from the PCR 
arrays, cycle threshold (CT) values of target genes were measured against the average 
CT values of the housekeeping genes b-actin, b-2 microglobulin, glyceraldehyde 3 
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phosphate dehydrogenase, b-glucuronidase, and a-heat shock protein 90. This method 
allowed for comparing relative gene expression among experimental groups, including 
ATII cells positive for mCherry protein, ATII cells negative for mCherry protein, and 
mock-infected cells. The differences between groups is represented by fold-change on 
Log2 scale.  
F. Quantitative Real-Time PCR 
 To measure expression of mRNA for additional target genes, total RNA was 
reverse-transcribed into cDNA using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Real-time quantitative PCR (Qpcr) experiments were performed 
by adding >6 ng of cDNA to murine specific gene probes (Life Technologies: Carlsbad, 
California). Gene expression CT values were normalized with respect to the 18s rRNA 
housekeeping gene. 
G. Immunofluorescence and Confocal Microscopy 
 To confirm the expression patterns obtained from real-time data, 
immunofluorescent staining was performed. ATII Cells were initially fixed in formalin and 
observed using confocal microscopy following primary antibody incubation against 
interferon gamma receptor (IFNgr) and nuclear staining with DAPI.  
H. In Vivo Imaging System 
 An In Vivo Imaging System was used to assess the intensity of red fluorescence 
protein in extracted whole lungs of mice at 0, 2, 4 and 6 days post infection.  
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IV. Results 
50,000 PFU is the dose sufficient to induce Acute Respiratory Distress (ARDS) at 6-
days post-PR8mCherry infection 
The PR8/mCherry/NS1 virus serves as a fluorescent tool which allows for 
differentiation between ATII cells that do and do not contain actively replicating virus. 
However, there was no previously established knowledge on viral dosage sufficient to 
induce clinical signs consistent with ARDS. A dose-response experiment was performed 
to determine the optimal concentration of PR8/mCherry/NS1 virus to use for intranasal 
infection. Previous studies have determined the LD50 of the PR8/mCherry/NSI virus in 
C57/B6 mice however the endpoint in this project was development of ARDS clinical 
signs11.  The clinical signs of ARDS in mice include consistent with hypoxemia, 
significant loss in body weight, increased water content in lungs, and reduced lung 
compliance12.  
 
 
A	
Figure 5 Changes in health parameters associated with ARDS 
A) The amount of fluid build-up in murine lungs were measured by at 6dpi at 
various viral doses B) Changes in murine body weight were recorded over a 
course of 6 days following infection in response to the viral doses administered C) 
The levels of oxygen saturation in murine lungs were measured over the course 
of influenza infection D) Comparison of a healthy (left) and PR8/mCherry virally 
infected lung (right) from WT mice 6dpi  
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dysfunction most consistent with an onset of ARDS. The 50,000 PFU dose was used in 
all proceeding experiments. 
Whole lungs of C57/B6 mice contain a large viral burden at 4 and 6 days post-infection 
 With the establishment of a viral dose, the next experimental parameter to 
determine was the most appropriate time-point for ATII cell isolation and gene-
expression studies. Assessment of viral burden at various time-points was performed to 
determine optimal time-points for isolating ATII cells. IVIS imaging revealed the intensity 
of red fluorescent proteins in whole lungs isolated at 6 dpi, 4 dpi, 2 dpi, and in a mock-
infected control lung. The peak fluorescence was measured from whole lung isolated at 
4 dpi. Although the peak fluorescence indicates the greatest viral burden, clinical signs 
are not most severe at 4 dpi but rather 6 dpi. This finding suggest that severe changes 
in the overall health of an in vivo model is not due to the influenza pathogen itself, but 
the changes in tissue integrity and immune function which result from the viral 
presence. Therefore, the 4 dpi time-point was selected to investigate changes the 
infection status and changes in gene expression in ATII cells that may contribute to the 
broader self-damaging host response. 
   
Figure 6 Fluorscence 
of the mCherry protein 
is highest at 4 dpi 
(right): Imaging of 
murine lungs ex-vivo 
showed that viral burden 
in the lung differed 
through the course of 
influenza infection 
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ATII isolation and characterization of subpopulations based on mCherry Status 
Isolation of ATII cells at 4dpi resulted in consistent collection of >106 cells per 
lung, which maintained a viability of at least 70%. The purity of ATII isolation was 
confirmed by flow cytometry, as the isolated population of cells consistently contained 
>90% CD45- cells, which is a marker used to negatively select for ATII cells. The 
isolated ATII populations were further sub-divided via flow-sorting. ATII cells were 
categorized as virus-positive or virus-negative based on the presence or absence of 
mCherry fluorescence.   
 
 
 
 
 
 
 
dCD45 
Figure 7 Isolation of ATII cells resulted in pure populations subdivided into mCherry+ 
and mCherry- groups: A) Flow panel shows crude cell populations (red) and pure ATII 
populations (black) B) Flow panel shows selective gating of whole ATII cell population into 
red fluorescent protein (RFP) positive or negative clusters C) Yields of RFP-containing ATII 
cells were slightly higher in ATII population unable to express miR-155 
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miR-155 is expressed at a higher level in flow-sorted mCherry+ ATII Cells than mCherry- 
and mock-infected ATII cells 
 Relative to ATII cells that did not contain mCherry protein from an infected lung 
and mock-infected populations, mCherry+ cells expressed the greatest amount of miR-
155. Normalization was performed relative to the endogenous control gene sno202. 
 
 
 
  
 
 
 
 
 
 
 
Upregulation of miR-155 is correlated with a robust downregulation of miR-155 target 
genes in miR-155 expressing mCherry- ATII cells  
Figure 8 (left) Mir-
155 expression is 
differs depending 
on mCherry 
presence in ATII 
cells A Fold change 
in expression of 
miR-155 was 
compared in 
mCherry+ and 
mCherry- ATII cells 
relative to a mock-
infected control at 4 
and 6 dpi. B 
Relative to mCherry- 
ATII cells, cold 
changes in miR-155 
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 Analysis of messenger-RNA levels in wild-type ATII cells revealed differing 
profiles of miR-155 target gene expression. Between mCherry+ and mCherry- ATII cells, 
the higher miR-155 levels in mCherry+ contributed to heterogeneous regulation of gene 
products, whereas the lower levels of miR-155 in mCherry- cells correlated to 
downregulation in most of the target genes.  
 
 
    
 
     Gene                                    Function                         Expression relative to WT mock 
Angiotensin receptor 1a 
(Agtr1a)- A02  
Regulates sodium-
potassium ATPase, as well 
as blood pressure and fluid 
balance 
Decreased in mCherry+ 
cells, no difference in 
mCherry- 
Interleukin-1 receptor 
associated kinase 3 
(Irak3)- C06 
Negative regulator of TLR 
system 
decreased in mCherry+ 
cells, no difference in 
mCherry- 
Figure 9 (below) Known target genes of miR-155 are differentially expressed within ATII 
cells of the same infected lung A) Heat-maps were generated showing differences in mRNA 
levels of miR-155 target genes from WT ATII cells B) List of the identities, location on heat 
map, functions, and change in regulation of the differentially regulated miR-155 target genes 
 
A	
B	
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SRY-Box 1 (Sox1)- F07 Transcriptional activator for 
RNA polymerase II 
Increased in mCherry+ 
cells, decreased in 
mCherry- 
Activation induced 
cytidine 
deaminase(Aicda)- B03 
Critical in B-cell 
developmental process of 
somatic hypermutation, 
gene conversion, and class-
switching 
Increased in mCherry+ 
cells, decreased in 
mCherry- 
MAF BZIP transcription 
factor B (Mafb)- C11 
Represses ETS-1 to 
regulate hematopoesis 
Increased in mCherry+ 
cells, decreased in 
mCherry- 
Runt related transcription 
factor 2 (Runx2)- E09 
Regulator in skeletal 
development and linked to 
fibrosis of lung tissue 
Decreased in mCherry+ 
cells, no difference in 
mCherry- 
Endothelin 1 (Edn1)- B05 Potent vasoconstrictor Increased in mCherry+ 
cells, decreased in 
mCherry- 
 
There is no significant change in mRNA levels between mock infected WT ATII cells 
and ATII cells with the miR-155 locus knock-out 
 To assess if wild-type ATII cells express miR-155 target genes differently than 
the ATII cells lacking miR-155 expression, the mRNA levels of miR-155 targets were 
compared in mock-infected populations of the two phenotypes.  
 
 
 
 
 
 
	
Differences	in	miR-155	Target	Expression	
between	WT	and	miR-155	KO	
Figure 10 (left) miR-155 has minimal 
influence on target gene expression 
in ATII cells of non-infected lungs Few 
miR-155 target genes were differentially 
regulated when comparing WT and miR-
155 KO ATII cells 
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Isolated from ATII-specific miR-155 KO mice, miR-155 target mRNA levels are 
heterogeneously expressed between mCherry+ and mCherry- ATII cells  
 Analysis of messenger-RNA levels in miR-155 ATII cells revealed similar profiles 
of miR-155 target gene expression. The absence of miR-155 expression contributed to 
up and down-regulation of targets genes in both mCherry+ and mCherry- ATII cells. The 
magnitude of target gene expression was lower in mCherry- ATII cells compared to the 
mCherry+ population. 
  
 
 
 
 
 
 
 
 
 
 
Figure 11 (below)  Known target genes of miR-155 are expressed heterogeneously in 
both A) Heat-maps were generated showing the differences in mRNA levels of miR-155 
target genes in miR-155 KO ATII celles B) List of the identities, location on heat map, 
functions, and change in regulation of the differentially regulated miR-155 target genes 
A	
B	
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Gene                                    Function                               Expression relative to KO mock 
Angiotensin receptor 1a 
(Aggtr1a)- A02 
Regulates sodium-
potassium ATPase, as well 
as blood pressure and fluid 
balance 
Decreased in mCherry+ 
cells, no difference in 
mCherry- 
Caspasse recruitment 
domain family 11 
(Card11)- A09 
Acttivates NF-kB, 
stimulation of T-cells and 
positively regulates 
apoptosis 
decreased in mCherry+ 
cells, decreased in 
mCherry- 
Dynein cytoplasmic 1 
intermediate chain 1 
(Dync1i1)- B04 
 
Factor in dynein cytoplasmic 
complex responsible for 
intracellular motility of 
organelles and vesicles 
along microtubules 
 
decreased in mCherry+ 
cells, increased in 
mCherry- 
Leucine zipper down-
regulated in cancer 1 
(Ldoc1)- C09 
Inhibits activation of NF-
kappaB 
No difference in mCherry+ 
cells, decreased in 
mCherry- 
Meis Homeobox 1 
(Meis1)- D03 
Transcriptional activator of 
PF4, a CXC chemokine 
decreased in mCherry+ 
cells, increased in 
mCherry- 
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V. Discussion 
Studying the dynamics of the host-response to influenza is an important 
component of managing infectious disease. Current treatment options for influenza 
patients are limited, especially in cases of ARDS, and current antivirals largely serve to 
alleviate symptoms and not treat the disease.  
 Since microRNAs act globally on regulating gene expression in eukaryotic cells, 
it is thought that they also play an important role in responding to pathogens. A hallmark 
feature of influenza pathology is the “cytokine storm” that occurs in the host in response 
to influenza replication13. miR-155 has been shown to play a role in regulating the 
expression of pre-inflammatory genes, so studying its role in an important cell type 
implicated during influenza infection may provide key insights to better management of 
the disease before severe clinical signs develop.  
This study found that mRNA of miR-155 targets are differentially expressed 
between ATII cells that contain replicating virus and do not contain replicating virus.  
Relative to mock-infected mice, miR-155 targets show a nearly global 
downregulation in mCherry- cells isolated from wild-type mice. Although the levels of 
miR-155 are lower in mCherry- cells than mCherry+, its role appears to be more 
profound in virus-negative cells. This was shown by the robust downregulation of 78 of 
the 84 miR-155 targets investigated. The regulatory effect of miR-155 in infected WT 
ATII cells did not differ greatly compared to infected miR-155 KO ATII cells. This finding 
suggests that the influenza virus suppresses the function of miR-155 at an intracellular 
level. However, there were four targets that showed differential expression in infected 
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WT ATII cells and were therefore regulated independently of influenza prescence. 
These targets were Irak3, Bcorl1, Runx2, and Zfp407. The role of Irak3 is linked to 
negative regulation of toll-like receptor signaling system14, so its downregulation may 
contribute to the pro-inflammatory microenvironment which occurs during influenza 
infection. Runx2 transcripts have been shown to be upregulated within ATII cells in 
clinical human cases of pulmonary fibrosis15, however with the 4dpi timepoint used in 
this experiment, such lung pathology was not evident and interestingly, Runx2 
transcripts were downregulated in both mCherry+ and mCherry- cells. Further 
investigations on Runx2 expression at 6dpi, when lung pathology is greater than 4dpi, 
may reveal differences in gene expression that occur independently of miR-155 
regulation. The consequences of miR-155 dependent downregulation of Bcorl1 and 
Zfp407 in response to influenza infection are not clear. 
 While differences exist in miR-155 target gene expression between infected WT 
and miR-155 KO ATII cells, it is important to note that only 3% of ATII cells from 
infected lungs contained actively replicated PR8/mCherry/NS1 virus. Therefore, the 
important effects of flu infection on the microenvironment in the distal lung may be more 
significant than the impact of actively infected cells alone. Although mCherry- ATII cells 
express less miR-155 than neighboring mCherry+ cells, it appears that the lack of virus 
allows miR-155 to regulate target genes more efficently than in virus-detected cells. 
 The increased expression of miR-155 in mCherry+ WT ATII cells may be partially 
due to the increased expression of Sox1, which is a known RNA polymerase II activator. 
RNA polymerase II is the enzyme in eukaryotic cells which is responsible for 
transcription of micro and small non-coding RNAs, including miR-15516. This finding 
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suggests that a positive-feedback mechanism contributes to the high expression of miR-
155 in mCherry+ cells, while miR-155 levels are lower in mCherry- cells which also 
display no difference in Sox1 mRNA expression compared to mock-infected ATII cells. 
MafB upregulation was observed in WT ATII cells containing virus, a factor known to 
interact with and repress the Ets1 transcription factor which is key in coordinating 
cytokine expression in immune cell activation17.  
The absense of miR-155 expression led to differential target gene expression in 
an ATII-specific miR-155 knockout model. The nearly global downregulation of miR-155 
targets in WT mCherry- ATII cells was not observed in the same population of the 
knockout model. However, the regulation of certain targets suggests that the regulation 
of miR-155 targets leads to inflammatory response that differs from that observed in the 
WT model. In mCherry- cells unable to express miR-155, Ldoc1 is downregulated while 
Card11 is upregulated. Both of these genes acts on the NF-kB pathway, an important 
immune cascade in respondingto pathogens. Ldoc1 inhibits the activation of the NF-kB 
transcription factor18 while Card11 activates it19, so the observed levels of expression 
indicate that the abundant virus-negative population is amplifying the NF-kB pathway in 
response to local virally infected cells. Furthermore, both Card11 and Ldoc1 positively 
regulate apoptosis, suggesting that induced cell death is being antagonistically 
regullted. However, Runx2 in this abundant virus-negative phenotype is higher than the 
locally infected cells, suggesting that there may be a greater risk of fibrosis development 
in the miR-155 knockout model. The level of regulation of these genes is unchanged in 
mCherry+ cells compared to a mock-infected population of ATII cells.  
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As miR-155 expression is greatest in mCherry+ cells, the difference of gene 
expression between WT and miR-155 KO ATII cells may provide insights on the 
interactions between influenza A virus and miR-155. The decreased levels of Irak3 
transcripts in the WT population of mCherry+ promotes the TLR signaling and in turn, 
activates the innate immune response. An overly activated innate immune response 
contributes damaging lung tissue that is often seen in cases of severe influenza 
disease. However, Runx2 is lower in the WT population which suggests that at 4dpi, 
pulmonary fibrosis may be less likely to development in contrast to the miR-155 KO ATII 
population. Increased Dync1i1 transcripts correlate to increased membrane traffic20 in 
the WT population, which suggests a change in cellular activity in response to the 
influenza pathogen. Lastly, in both groups of mCherry+ ATII cells, the level of Angtr1a 
transcripts was downregulated . As a part of the renin-angiotensin system, this 
downregulated receptor could be contributing to vasodilation and suppressed 
aldosterone levels, which are responses that lead to infiltration of inflammatory markers 
in local tissue21. Influenza A virus acts to block the effects of the angiotensin receptor 
regardless of miR-155 expression.  
 Future directions for this study include the validation of transcriptomic data via 
phenotyping experiments and transitioning into the investigation of changes to miR-155 
regulation at 6dpi. For example, the level of Runx2 expression at 6dpi may serve as a 
better indicator of pulmonary fibrosis development than the levels at 4dpi, when severe 
lung pathology is not evident in a mouse model. In addition, the lung compliances will 
be measured between the two strains of mice utliized in this study in order to assess 
differences in clinical sign development. Analysis of bronchoaleveolar fluids from both 
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strains will also provide insights to whether differences in miR-155 expression in the 
alveolar space influence the environment of infected whole lungs. Conducting these 
studies will hopefully illuminate potential therapeutic options that alleviate the role of 
miR-155 in the inflammatory cascade that leads to cases of influenza disease. 
Additonally, this potential host-focused therapeutic could serve as an alternative that 
provide a treatment option independent of viral strain and disease severity.  
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IX. Supplemental Material 
RT² Profiler™ PCR Array Mouse miR-155 Targets:  
Position-RefSeq Number-Symbol-Description 
A01 NM_177762 Aak1 AP2 associated kinase 1 
A02 NM_177322 Agtr1a Angiotensin II receptor, type 1a 
A03 NM_009645 Aicda Activation-induced cytidine deaminase 
A04 NM_007462 Apc Adenomatosis polyposis coli 
A05 NM_175251 Arid2 AT rich interactive domain 2 (ARID, RFX-
like) 
A06 NM_019514 Astn2 Astrotactin 2 
A07 NM_007520 Bach1 BTB and CNC homology 1 
A08 NM_178782 Bcorl1 BCL6 co-repressor-like 1 
A09 NM_175362 Card11 Caspase recruitment domain family, 
member 11 
A10 NM_009883 Cebpb CCAAT/enhancer binding protein 
(C/EBP), beta 
A11 NM_177224 Chd9 Chromodomain helicase DNA binding 
protein 9 
A12 NM_134002 Csnk1g2 Casein kinase 1, gamma 2 
B01 NM_010516 Cyr61 Cysteine rich protein 61 
B02 NM_029585 Det1 De-etiolated homolog 1 (Arabidopsis) 
B03 NM_026191 Dhx40 DEAH (Asp-Glu-Ala-His) box polypeptide 
40 
B04 NM_010063 Dync1i1 Dynein cytoplasmic 1 intermediate chain 
1 
B05 NM_010104 Edn1 Endothelin 1 
B06 NM_011808 Ets1 E26 avian leukemia oncogene 1, 5' domain 
B07 NM_010175 Fadd Fas (TNFRSF6)-associated via death 
domain 
B08 NM_008008 Fgf7 Fibroblast growth factor 7 
B09 NM_019740 Foxo3 Forkhead box O3 
B10 NM_011816 G3bp2 GTPase activating protein (SH3 domain) 
binding protein 2 
B11 NM_013526 Gdf6 Growth differentiation factor 6 
B12 NM_010437 Hivep2 Human immunodeficiency virus type I 
enhancer binding protein 2 
C01 NM_198090 Hnrnpa3 Heterogeneous nuclear 
ribonucleoprotein A3 
C02 NM_010511 Ifngr1 Interferon gamma receptor 1 
C03 NM_019777 Ikbke Inhibitor of kappaB kinase epsilon 
C04 NM_010561 Ilf3 Interleukin enhancer binding factor 3 
C05 NM_010566 Inpp5d Inositol polyphosphate-5-phosphatase D 
C06 NM_028679 Irak3 Interleukin-1 receptor-associated kinase 3 
C07 NM_021878 Jarid2 Jumonji, AT rich interactive domain 2 
C08 NM_021284 Kras V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
C09 NM_001018087 Ldoc1 Leucine zipper, down-regulated in 
cancer 1 
C10 NM_175116 Lpar6 Lysophosphatidic acid receptor 6 
C11 NM_010658 Mafb V-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B (avian) 
C12 NM_010771 Matr3 Matrin 3 
D01 NM_010788 Mecp2 Methyl CpG binding protein 2 
D02 NM_001033713 Mef2a Myocyte enhancer factor 2A 
D03 NM_010789 Meis1 Meis homeobox 1 
D04 NM_026810 Mlh1 MutL homolog 1 (E. coli) 
D05 NM_008628 Msh2 MutS homolog 2 (E. coli) 
D06 NM_010830 Msh6 MutS homolog 6 (E. coli) 
D07 NM_010848 Myb Myeloblastosis oncogene 
D08 NM_019472 Myo10 Myosin X 
D09 NM_022996 Ndfip1 Nedd4 family interacting protein 1 
D10 NM_010900 Nfatc2ip Nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 2 interacting protein 
3 
Position RefSeq Number Symbol Description 
D11 NM_021361 Nova1 Neuro-oncological ventral antigen 1 
D12 NM_013626 Pam Peptidylglycine alpha-amidating 
monooxygenase 
E01 NM_011063 Pea15a Phosphoprotein enriched in astrocytes 
15A 
E02 NM_023324 Peli1 Pellino 1 
E03 NM_172303 Jade1 PHD finger protein 17 
E04 NM_176916 Pld5 Phospholipase D family, member 5 
E05 NM_024457 Rap1b RAS related protein 1b 
E06 NM_016802 Rhoa Ras homolog gene family, member A 
E07 NM_009068 Ripk1 Receptor (TNFRSF)-interacting serine-
threonine kinase 1 
E08 NM_001177869 Rreb1 Ras responsive element binding 
protein 1 
E09 NM_009820 Runx2 Runt related transcription factor 2 
E10 NM_001127725 Sec14l5 SEC14-like 5 (S. cerevisiae) 
E11 NM_001009818 Sept11 Septin 11 
E12 NM_011355 Spi1 SFFV proviral integration 1 
F01 NM_011385 Ski Ski sarcoma viral oncogene homolog (avian) 
F02 NM_028151 Skiv2l2 Superkiller viralicidic activity 2-like 2 (S. 
cerevisiae) 
F03 NM_008539 Smad1 MAD homolog 1 (Drosophila) 
F04 NM_010754 Smad2 MAD homolog 2 (Drosophila) 
F05 NM_008541 Smad5 MAD homolog 5 (Drosophila) 
F06 NM_009896 Socs1 Suppressor of cytokine signaling 1 
F07 NM_009233 Sox1 SRY-box containing gene 1 
F08 NM_172675 Stx16 Syntaxin 16 
F09 NM_172440 Stxbp5l Syntaxin binding protein 5-like 
F10 NM_138667 Tab2 TGF-beta activated kinase 1/MAP3K7 
binding protein 2 
F11 NM_026456 Tceb1 Transcription elongation factor B (SIII), 
polypeptide 1 
F12 NM_011600 Tle4 Transducin-like enhancer of split 4, homolog 
of Drosophila E(spl) 
G01 NM_145375 Tm6sf1 Transmembrane 6 superfamily member 
1 
G02 NM_024214 Tomm20 Translocase of outer mitochondrial 
membrane 20 homolog (yeast) 
G03 NM_021897 Trp53inp1 Transformation related protein 53 
inducible nuclear protein 1 
G04 NM_172298 Tshz3 Teashirt zinc finger family member 3 
G05 NM_027192 Ttl Tubulin tyrosine ligase 
G06 NM_025650 Uqcr11 Ubiquinol-cytochrome c reductase, 
complex III subunit XI 
G07 NM_021522 Usp14 Ubiquitin specific peptidase 14 
G08 NM_177832 Zfp236 Zinc finger protein 236 
G09 NM_001033341 Zfp407 Zinc finger protein 407 
G10 NM_201609 Zfp652 Zinc finger protein 652 
G11 NM_009575 Zic3 Zinc finger protein of the cerebellum 3 
G12 NM_029498 Zmym2 Zinc finger, MYM-type 2 
H01 NM_007393 Actb Actin, beta 
H02 NM_009735 B2m Beta-2 microglobulin 
H03 NM_008084 Gapdh Glyceraldehyde-3-phosphate 
dehydrogenase 
H04 NM_010368 Gusb Glucuronidase, beta 
H05 NM_008302 Hsp90ab1 Heat shock protein 90 alpha 
(cytosolic), class B member 1 
H06 SA_00106 MGDC Mouse Genomic DNA Contamination 
H07 SA_00104 RTC Reverse Transcription Control 
H08 SA_00104 RTC Reverse Transcription Control 
H09 SA_00104 RTC Reverse Transcription Control 
H10 SA_00103 PPC Positive PCR Control 
H11 SA_00103 PPC Positive PCR Control 
H12 SA_00103 PPC Positive PCR Control 
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